nodes	percent_of_prediction	percent_of_DWPC	metapath
Everolimus—MTOR—Oncostatin M Signaling Pathway—KRAS—bile duct cancer	0.00281	0.00281	CbGpPWpGaD
Everolimus—MTOR—mTOR signaling pathway—KRAS—bile duct cancer	0.00278	0.00278	CbGpPWpGaD
Everolimus—MTOR—ErbB Signaling Pathway—HRAS—bile duct cancer	0.00277	0.00277	CbGpPWpGaD
Everolimus—FKBP1A—Spinal Cord Injury—TP53—bile duct cancer	0.00276	0.00276	CbGpPWpGaD
Everolimus—MTOR—IRS-mediated signalling—NRAS—bile duct cancer	0.00264	0.00264	CbGpPWpGaD
Everolimus—MTOR—IRS-related events—NRAS—bile duct cancer	0.00256	0.00256	CbGpPWpGaD
Everolimus—FKBP1A—Disease—IDH1—bile duct cancer	0.00254	0.00254	CbGpPWpGaD
Everolimus—MTOR—IRS-related events triggered by IGF1R—NRAS—bile duct cancer	0.00254	0.00254	CbGpPWpGaD
Everolimus—FKBP1A—Spinal Cord Injury—IL6—bile duct cancer	0.00252	0.00252	CbGpPWpGaD
Everolimus—MTOR—Oncostatin M Signaling Pathway—TP53—bile duct cancer	0.0025	0.0025	CbGpPWpGaD
Everolimus—MTOR—IGF1R signaling cascade—NRAS—bile duct cancer	0.00247	0.00247	CbGpPWpGaD
Everolimus—MTOR—Insulin receptor signalling cascade—NRAS—bile duct cancer	0.00247	0.00247	CbGpPWpGaD
Everolimus—MTOR—MicroRNAs in cardiomyocyte hypertrophy—TGFB1—bile duct cancer	0.00247	0.00247	CbGpPWpGaD
Everolimus—MTOR—Oncostatin M Signaling Pathway—HRAS—bile duct cancer	0.00239	0.00239	CbGpPWpGaD
Everolimus—MTOR—AMPK Signaling—TP53—bile duct cancer	0.00238	0.00238	CbGpPWpGaD
Everolimus—MTOR—Constitutive PI3K/AKT Signaling in Cancer—EGFR—bile duct cancer	0.00238	0.00238	CbGpPWpGaD
Everolimus—MTOR—TSH signaling pathway—HRAS—bile duct cancer	0.00236	0.00236	CbGpPWpGaD
Everolimus—MTOR—mTOR signaling pathway—HRAS—bile duct cancer	0.00236	0.00236	CbGpPWpGaD
Everolimus—MTOR—Signaling by SCF-KIT—ERBB2—bile duct cancer	0.00231	0.00231	CbGpPWpGaD
Everolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—TGFB1—bile duct cancer	0.00228	0.00228	CbGpPWpGaD
Everolimus—MTOR—IRS-mediated signalling—KRAS—bile duct cancer	0.00227	0.00227	CbGpPWpGaD
Everolimus—MTOR—CDC42 signaling events—HRAS—bile duct cancer	0.00225	0.00225	CbGpPWpGaD
Everolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—EGFR—bile duct cancer	0.00223	0.00223	CbGpPWpGaD
Everolimus—MTOR—ErbB1 downstream signaling—NRAS—bile duct cancer	0.00223	0.00223	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling of activated FGFR—ERBB2—bile duct cancer	0.00221	0.00221	CbGpPWpGaD
Everolimus—MTOR—IRS-related events—KRAS—bile duct cancer	0.00221	0.00221	CbGpPWpGaD
Everolimus—MTOR—VEGFA-VEGFR2 Pathway—NRAS—bile duct cancer	0.00219	0.00219	CbGpPWpGaD
Everolimus—MTOR—IRS-related events triggered by IGF1R—KRAS—bile duct cancer	0.00219	0.00219	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB4—ERBB2—bile duct cancer	0.00218	0.00218	CbGpPWpGaD
Everolimus—MTOR—PI-3K cascade—EGFR—bile duct cancer	0.00214	0.00214	CbGpPWpGaD
Everolimus—MTOR—Leptin signaling pathway—HRAS—bile duct cancer	0.00213	0.00213	CbGpPWpGaD
Everolimus—MTOR—Insulin receptor signalling cascade—KRAS—bile duct cancer	0.00213	0.00213	CbGpPWpGaD
Everolimus—MTOR—IGF1R signaling cascade—KRAS—bile duct cancer	0.00213	0.00213	CbGpPWpGaD
Everolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—KRAS—bile duct cancer	0.00211	0.00211	CbGpPWpGaD
Everolimus—MTOR—PI3K/AKT activation—EGFR—bile duct cancer	0.00209	0.00209	CbGpPWpGaD
Everolimus—MTOR—Downstream signal transduction—ERBB2—bile duct cancer	0.00208	0.00208	CbGpPWpGaD
Everolimus—MTOR—GAB1 signalosome—EGFR—bile duct cancer	0.00208	0.00208	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—RNF43—bile duct cancer	0.00207	0.00207	CbGpPWpGaD
Everolimus—MTOR—Signaling by VEGF—NRAS—bile duct cancer	0.00207	0.00207	CbGpPWpGaD
Everolimus—MTOR—Senescence and Autophagy in Cancer—TGFB1—bile duct cancer	0.00207	0.00207	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR—ERBB2—bile duct cancer	0.00207	0.00207	CbGpPWpGaD
Everolimus—MTOR—EGF/EGFR Signaling Pathway—ERBB2—bile duct cancer	0.00207	0.00207	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB2—ERBB2—bile duct cancer	0.00206	0.00206	CbGpPWpGaD
Everolimus—MTOR—Signaling by Insulin receptor—NRAS—bile duct cancer	0.00206	0.00206	CbGpPWpGaD
Everolimus—MTOR—DAP12 signaling—ERBB2—bile duct cancer	0.00205	0.00205	CbGpPWpGaD
Everolimus—MTOR—Role of LAT2/NTAL/LAB on calcium mobilization—EGFR—bile duct cancer	0.00203	0.00203	CbGpPWpGaD
Everolimus—MTOR—ErbB1 downstream signaling—EGFR—bile duct cancer	0.00203	0.00203	CbGpPWpGaD
Everolimus—MTOR—Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)—HRAS—bile duct cancer	0.00202	0.00202	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—ERBB2—bile duct cancer	0.00202	0.00202	CbGpPWpGaD
Everolimus—MTOR—Signaling by SCF-KIT—MMP9—bile duct cancer	0.00198	0.00198	CbGpPWpGaD
Everolimus—MTOR—IRS-mediated signalling—HRAS—bile duct cancer	0.00193	0.00193	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR in disease—ERBB2—bile duct cancer	0.00193	0.00193	CbGpPWpGaD
Everolimus—MTOR—DAP12 interactions—ERBB2—bile duct cancer	0.00193	0.00193	CbGpPWpGaD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—ERBB2—bile duct cancer	0.00193	0.00193	CbGpPWpGaD
Everolimus—MTOR—ErbB1 downstream signaling—KRAS—bile duct cancer	0.00192	0.00192	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR—ERBB2—bile duct cancer	0.00191	0.00191	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR in Cancer—ERBB2—bile duct cancer	0.00189	0.00189	CbGpPWpGaD
Everolimus—MTOR—VEGFA-VEGFR2 Pathway—KRAS—bile duct cancer	0.00189	0.00189	CbGpPWpGaD
Everolimus—MTOR—Signaling by PDGF—ERBB2—bile duct cancer	0.00188	0.00188	CbGpPWpGaD
Everolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—TP53—bile duct cancer	0.00188	0.00188	CbGpPWpGaD
Everolimus—MTOR—IRS-related events—HRAS—bile duct cancer	0.00188	0.00188	CbGpPWpGaD
Everolimus—MTOR—IRS-related events triggered by IGF1R—HRAS—bile duct cancer	0.00186	0.00186	CbGpPWpGaD
Everolimus—MTOR—IRS-mediated signalling—IL6—bile duct cancer	0.00185	0.00185	CbGpPWpGaD
Everolimus—MTOR—Insulin receptor signalling cascade—HRAS—bile duct cancer	0.00181	0.00181	CbGpPWpGaD
Everolimus—MTOR—IGF1R signaling cascade—HRAS—bile duct cancer	0.00181	0.00181	CbGpPWpGaD
Everolimus—MTOR—IRS-related events—IL6—bile duct cancer	0.0018	0.0018	CbGpPWpGaD
Everolimus—MTOR—B Cell Activation—ERBB2—bile duct cancer	0.00178	0.00178	CbGpPWpGaD
Everolimus—MTOR—Signaling by VEGF—KRAS—bile duct cancer	0.00178	0.00178	CbGpPWpGaD
Everolimus—MTOR—IRS-related events triggered by IGF1R—IL6—bile duct cancer	0.00178	0.00178	CbGpPWpGaD
Everolimus—MTOR—Signaling by Insulin receptor—KRAS—bile duct cancer	0.00177	0.00177	CbGpPWpGaD
Everolimus—MTOR—Signaling by SCF-KIT—NRAS—bile duct cancer	0.00176	0.00176	CbGpPWpGaD
Everolimus—MTOR—IGF1R signaling cascade—IL6—bile duct cancer	0.00173	0.00173	CbGpPWpGaD
Everolimus—MTOR—Insulin receptor signalling cascade—IL6—bile duct cancer	0.00173	0.00173	CbGpPWpGaD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—ERBB2—bile duct cancer	0.00171	0.00171	CbGpPWpGaD
Everolimus—MTOR—Senescence and Autophagy in Cancer—TP53—bile duct cancer	0.0017	0.0017	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling of activated FGFR—NRAS—bile duct cancer	0.00168	0.00168	CbGpPWpGaD
Everolimus—MTOR—Disease—RNF43—bile duct cancer	0.00166	0.00166	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB4—NRAS—bile duct cancer	0.00166	0.00166	CbGpPWpGaD
Everolimus—MTOR—ErbB1 downstream signaling—HRAS—bile duct cancer	0.00163	0.00163	CbGpPWpGaD
Everolimus—MTOR—Senescence and Autophagy in Cancer—HRAS—bile duct cancer	0.00163	0.00163	CbGpPWpGaD
Everolimus—MTOR—VEGFA-VEGFR2 Pathway—HRAS—bile duct cancer	0.0016	0.0016	CbGpPWpGaD
Everolimus—MTOR—Signaling by SCF-KIT—EGFR—bile duct cancer	0.0016	0.0016	CbGpPWpGaD
Everolimus—MTOR—Downstream signal transduction—NRAS—bile duct cancer	0.00158	0.00158	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR—NRAS—bile duct cancer	0.00157	0.00157	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB2—NRAS—bile duct cancer	0.00157	0.00157	CbGpPWpGaD
Everolimus—MTOR—Senescence and Autophagy in Cancer—IL6—bile duct cancer	0.00156	0.00156	CbGpPWpGaD
Everolimus—MTOR—DAP12 signaling—NRAS—bile duct cancer	0.00156	0.00156	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—NRAS—bile duct cancer	0.00154	0.00154	CbGpPWpGaD
Everolimus—MTOR—VEGFA-VEGFR2 Pathway—IL6—bile duct cancer	0.00154	0.00154	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling of activated FGFR—EGFR—bile duct cancer	0.00153	0.00153	CbGpPWpGaD
Everolimus—MTOR—Integrated Breast Cancer Pathway—EGFR—bile duct cancer	0.00152	0.00152	CbGpPWpGaD
Everolimus—MTOR—Signaling by VEGF—HRAS—bile duct cancer	0.00151	0.00151	CbGpPWpGaD
Everolimus—MTOR—Signaling by SCF-KIT—KRAS—bile duct cancer	0.00151	0.00151	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB4—EGFR—bile duct cancer	0.00151	0.00151	CbGpPWpGaD
Everolimus—MTOR—Signaling by Insulin receptor—HRAS—bile duct cancer	0.0015	0.0015	CbGpPWpGaD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—NRAS—bile duct cancer	0.00147	0.00147	CbGpPWpGaD
Everolimus—MTOR—DAP12 interactions—NRAS—bile duct cancer	0.00147	0.00147	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR in disease—NRAS—bile duct cancer	0.00147	0.00147	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR—NRAS—bile duct cancer	0.00145	0.00145	CbGpPWpGaD
Everolimus—MTOR—Signaling by VEGF—IL6—bile duct cancer	0.00145	0.00145	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling of activated FGFR—KRAS—bile duct cancer	0.00145	0.00145	CbGpPWpGaD
Everolimus—MTOR—Downstream signal transduction—EGFR—bile duct cancer	0.00144	0.00144	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR in Cancer—NRAS—bile duct cancer	0.00144	0.00144	CbGpPWpGaD
Everolimus—MTOR—Signaling by Insulin receptor—IL6—bile duct cancer	0.00144	0.00144	CbGpPWpGaD
Everolimus—MTOR—EGF/EGFR Signaling Pathway—EGFR—bile duct cancer	0.00143	0.00143	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR—EGFR—bile duct cancer	0.00143	0.00143	CbGpPWpGaD
Everolimus—MTOR—Signaling by PDGF—NRAS—bile duct cancer	0.00143	0.00143	CbGpPWpGaD
Everolimus—MTOR—Integrated Breast Cancer Pathway—KRAS—bile duct cancer	0.00143	0.00143	CbGpPWpGaD
Everolimus—MTOR—Disease—IDH1—bile duct cancer	0.00143	0.00143	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB2—EGFR—bile duct cancer	0.00143	0.00143	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB4—KRAS—bile duct cancer	0.00143	0.00143	CbGpPWpGaD
Everolimus—MTOR—DAP12 signaling—EGFR—bile duct cancer	0.00142	0.00142	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—EGFR—bile duct cancer	0.0014	0.0014	CbGpPWpGaD
Everolimus—MTOR—Downstream signal transduction—KRAS—bile duct cancer	0.00136	0.00136	CbGpPWpGaD
Everolimus—MTOR—B Cell Activation—NRAS—bile duct cancer	0.00136	0.00136	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR—KRAS—bile duct cancer	0.00135	0.00135	CbGpPWpGaD
Everolimus—MTOR—EGF/EGFR Signaling Pathway—KRAS—bile duct cancer	0.00135	0.00135	CbGpPWpGaD
Everolimus—FKBP1A—Disease—TGFBR2—bile duct cancer	0.00135	0.00135	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB2—KRAS—bile duct cancer	0.00135	0.00135	CbGpPWpGaD
Everolimus—MTOR—DAP12 signaling—KRAS—bile duct cancer	0.00134	0.00134	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR in disease—EGFR—bile duct cancer	0.00134	0.00134	CbGpPWpGaD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—EGFR—bile duct cancer	0.00134	0.00134	CbGpPWpGaD
Everolimus—MTOR—DAP12 interactions—EGFR—bile duct cancer	0.00134	0.00134	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR—EGFR—bile duct cancer	0.00132	0.00132	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—KRAS—bile duct cancer	0.00132	0.00132	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—ERBB2—bile duct cancer	0.00131	0.00131	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR in Cancer—EGFR—bile duct cancer	0.00131	0.00131	CbGpPWpGaD
Everolimus—MTOR—Signaling by PDGF—EGFR—bile duct cancer	0.00131	0.00131	CbGpPWpGaD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—NRAS—bile duct cancer	0.0013	0.0013	CbGpPWpGaD
Everolimus—MTOR—Signaling by SCF-KIT—HRAS—bile duct cancer	0.00129	0.00129	CbGpPWpGaD
Everolimus—FKBP1A—Disease—SMAD4—bile duct cancer	0.00128	0.00128	CbGpPWpGaD
Everolimus—MTOR—Integrated Breast Cancer Pathway—TP53—bile duct cancer	0.00127	0.00127	CbGpPWpGaD
Everolimus—MTOR—BDNF signaling pathway—HRAS—bile duct cancer	0.00126	0.00126	CbGpPWpGaD
Everolimus—MTOR—DAP12 interactions—KRAS—bile duct cancer	0.00126	0.00126	CbGpPWpGaD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—KRAS—bile duct cancer	0.00126	0.00126	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR in disease—KRAS—bile duct cancer	0.00126	0.00126	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR—KRAS—bile duct cancer	0.00125	0.00125	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR in Cancer—KRAS—bile duct cancer	0.00124	0.00124	CbGpPWpGaD
Everolimus—MTOR—B Cell Activation—EGFR—bile duct cancer	0.00124	0.00124	CbGpPWpGaD
Everolimus—MTOR—Signaling by PDGF—KRAS—bile duct cancer	0.00123	0.00123	CbGpPWpGaD
Everolimus—MTOR—Signaling by SCF-KIT—IL6—bile duct cancer	0.00123	0.00123	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling of activated FGFR—HRAS—bile duct cancer	0.00123	0.00123	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB4—HRAS—bile duct cancer	0.00121	0.00121	CbGpPWpGaD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—EGFR—bile duct cancer	0.00118	0.00118	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling of activated FGFR—IL6—bile duct cancer	0.00118	0.00118	CbGpPWpGaD
Everolimus—MTOR—B Cell Activation—KRAS—bile duct cancer	0.00117	0.00117	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—RNF43—bile duct cancer	0.00116	0.00116	CbGpPWpGaD
Everolimus—MTOR—Insulin Signaling—HRAS—bile duct cancer	0.00116	0.00116	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB4—IL6—bile duct cancer	0.00116	0.00116	CbGpPWpGaD
Everolimus—MTOR—Downstream signal transduction—HRAS—bile duct cancer	0.00116	0.00116	CbGpPWpGaD
Everolimus—MTOR—EGF/EGFR Signaling Pathway—HRAS—bile duct cancer	0.00115	0.00115	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR—HRAS—bile duct cancer	0.00115	0.00115	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB2—HRAS—bile duct cancer	0.00115	0.00115	CbGpPWpGaD
Everolimus—MTOR—DAP12 signaling—HRAS—bile duct cancer	0.00114	0.00114	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—HRAS—bile duct cancer	0.00112	0.00112	CbGpPWpGaD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—KRAS—bile duct cancer	0.00112	0.00112	CbGpPWpGaD
Everolimus—MTOR—Downstream signal transduction—IL6—bile duct cancer	0.00111	0.00111	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR—IL6—bile duct cancer	0.0011	0.0011	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB2—IL6—bile duct cancer	0.0011	0.0011	CbGpPWpGaD
Everolimus—MTOR—DAP12 signaling—IL6—bile duct cancer	0.00109	0.00109	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR in disease—HRAS—bile duct cancer	0.00107	0.00107	CbGpPWpGaD
Everolimus—MTOR—DAP12 interactions—HRAS—bile duct cancer	0.00107	0.00107	CbGpPWpGaD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—HRAS—bile duct cancer	0.00107	0.00107	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR—HRAS—bile duct cancer	0.00106	0.00106	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR in Cancer—HRAS—bile duct cancer	0.00105	0.00105	CbGpPWpGaD
Everolimus—MTOR—Signaling by PDGF—HRAS—bile duct cancer	0.00105	0.00105	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR in disease—IL6—bile duct cancer	0.00103	0.00103	CbGpPWpGaD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—IL6—bile duct cancer	0.00103	0.00103	CbGpPWpGaD
Everolimus—MTOR—DAP12 interactions—IL6—bile duct cancer	0.00103	0.00103	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR—IL6—bile duct cancer	0.00102	0.00102	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR in Cancer—IL6—bile duct cancer	0.00101	0.00101	CbGpPWpGaD
Everolimus—MTOR—Signaling by PDGF—IL6—bile duct cancer	0.001	0.001	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—NRAS—bile duct cancer	0.000999	0.000999	CbGpPWpGaD
Everolimus—MTOR—B Cell Activation—HRAS—bile duct cancer	0.000992	0.000992	CbGpPWpGaD
Everolimus—FKBP1A—Disease—NOS2—bile duct cancer	0.000952	0.000952	CbGpPWpGaD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—HRAS—bile duct cancer	0.00095	0.00095	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—TGFBR2—bile duct cancer	0.000946	0.000946	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—GNAS—bile duct cancer	0.000913	0.000913	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—EGFR—bile duct cancer	0.00091	0.00091	CbGpPWpGaD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—IL6—bile duct cancer	0.000909	0.000909	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—SMAD4—bile duct cancer	0.000896	0.000896	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—KRAS—bile duct cancer	0.000859	0.000859	CbGpPWpGaD
Everolimus—MTOR—Cellular responses to stress—TP53—bile duct cancer	0.000814	0.000814	CbGpPWpGaD
Everolimus—MTOR—Disease—TGFBR2—bile duct cancer	0.00076	0.00076	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—FAR2—bile duct cancer	0.000756	0.000756	CbGpPWpGaD
Everolimus—MTOR—Immune System—HGF—bile duct cancer	0.000756	0.000756	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—ERBB2—bile duct cancer	0.000749	0.000749	CbGpPWpGaD
Everolimus—MTOR—Cellular responses to stress—IL6—bile duct cancer	0.000745	0.000745	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—HRAS—bile duct cancer	0.000731	0.000731	CbGpPWpGaD
Everolimus—MTOR—Disease—SMAD4—bile duct cancer	0.000719	0.000719	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—ERBB2—bile duct cancer	0.000719	0.000719	CbGpPWpGaD
Everolimus—FKBP1A—Disease—ERBB2—bile duct cancer	0.000716	0.000716	CbGpPWpGaD
Everolimus—FKBP1A—Disease—PTGS2—bile duct cancer	0.0007	0.0007	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—IL6—bile duct cancer	0.000699	0.000699	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—NRAS—bile duct cancer	0.00057	0.00057	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—NRAS—bile duct cancer	0.000547	0.000547	CbGpPWpGaD
Everolimus—FKBP1A—Disease—NRAS—bile duct cancer	0.000545	0.000545	CbGpPWpGaD
Everolimus—MTOR—Disease—NOS2—bile duct cancer	0.000535	0.000535	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—TGFBR2—bile duct cancer	0.000532	0.000532	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—EGFR—bile duct cancer	0.000519	0.000519	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—GNAS—bile duct cancer	0.000513	0.000513	CbGpPWpGaD
Everolimus—FKBP1A—Disease—TGFB1—bile duct cancer	0.000506	0.000506	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—SMAD4—bile duct cancer	0.000504	0.000504	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—ERBB2—bile duct cancer	0.000501	0.000501	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—EGFR—bile duct cancer	0.000498	0.000498	CbGpPWpGaD
Everolimus—FKBP1A—Disease—EGFR—bile duct cancer	0.000496	0.000496	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—KRAS—bile duct cancer	0.00049	0.00049	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—KRAS—bile duct cancer	0.000471	0.000471	CbGpPWpGaD
Everolimus—FKBP1A—Disease—KRAS—bile duct cancer	0.000469	0.000469	CbGpPWpGaD
Everolimus—MTOR—Immune System—ERBB2—bile duct cancer	0.000436	0.000436	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—MMP9—bile duct cancer	0.00043	0.00043	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—HRAS—bile duct cancer	0.000417	0.000417	CbGpPWpGaD
Everolimus—MTOR—Disease—ERBB2—bile duct cancer	0.000403	0.000403	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—HRAS—bile duct cancer	0.0004	0.0004	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—IL6—bile duct cancer	0.000399	0.000399	CbGpPWpGaD
Everolimus—FKBP1A—Disease—HRAS—bile duct cancer	0.000398	0.000398	CbGpPWpGaD
Everolimus—MTOR—Disease—PTGS2—bile duct cancer	0.000394	0.000394	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—NRAS—bile duct cancer	0.000381	0.000381	CbGpPWpGaD
Everolimus—FKBP1A—Disease—IL6—bile duct cancer	0.000381	0.000381	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—IDH2—bile duct cancer	0.000369	0.000369	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—TGFB1—bile duct cancer	0.000354	0.000354	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—EGFR—bile duct cancer	0.000347	0.000347	CbGpPWpGaD
Everolimus—MTOR—Immune System—NRAS—bile duct cancer	0.000332	0.000332	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—KRAS—bile duct cancer	0.000328	0.000328	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—IDH1—bile duct cancer	0.000318	0.000318	CbGpPWpGaD
Everolimus—MTOR—Disease—NRAS—bile duct cancer	0.000306	0.000306	CbGpPWpGaD
Everolimus—MTOR—Immune System—EGFR—bile duct cancer	0.000302	0.000302	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—TP53—bile duct cancer	0.000292	0.000292	CbGpPWpGaD
Everolimus—MTOR—Immune System—KRAS—bile duct cancer	0.000286	0.000286	CbGpPWpGaD
Everolimus—MTOR—Disease—TGFB1—bile duct cancer	0.000285	0.000285	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—ERBB2—bile duct cancer	0.000282	0.000282	CbGpPWpGaD
Everolimus—MTOR—Disease—EGFR—bile duct cancer	0.000279	0.000279	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—HRAS—bile duct cancer	0.000279	0.000279	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—IL6—bile duct cancer	0.000267	0.000267	CbGpPWpGaD
Everolimus—MTOR—Disease—KRAS—bile duct cancer	0.000264	0.000264	CbGpPWpGaD
Everolimus—MTOR—Immune System—HRAS—bile duct cancer	0.000243	0.000243	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—MMP9—bile duct cancer	0.000242	0.000242	CbGpPWpGaD
Everolimus—MTOR—Immune System—IL6—bile duct cancer	0.000232	0.000232	CbGpPWpGaD
Everolimus—MTOR—Disease—HRAS—bile duct cancer	0.000224	0.000224	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—NRAS—bile duct cancer	0.000214	0.000214	CbGpPWpGaD
Everolimus—MTOR—Disease—IL6—bile duct cancer	0.000214	0.000214	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—SLC5A5—bile duct cancer	0.00021	0.00021	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—TGFB1—bile duct cancer	0.000199	0.000199	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—EGFR—bile duct cancer	0.000195	0.000195	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—KRAS—bile duct cancer	0.000185	0.000185	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—TP53—bile duct cancer	0.000164	0.000164	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—GNAS—bile duct cancer	0.000163	0.000163	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—HRAS—bile duct cancer	0.000157	0.000157	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—IL6—bile duct cancer	0.00015	0.00015	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PTGS2—bile duct cancer	8.74e-05	8.74e-05	CbGpPWpGaD
